Lefaucheur Jean-Pascal, Antal Andrea, Ayache Samar S, Benninger David H, Brunelin Jérôme, Cogiamanian Filippo, Cotelli Maria, De Ridder Dirk, Ferrucci Roberta, Langguth Berthold, Marangolo Paola, Mylius Veit, Nitsche Michael A, Padberg Frank, Palm Ulrich, Poulet Emmanuel, Priori Alberto, Rossi Simone, Schecklmann Martin, Vanneste Sven, Ziemann Ulf, Garcia-Larrea Luis, Paulus Walter
Department of Physiology, Henri Mondor Hospital, Assistance Publique - Hôpitaux de Paris, Créteil, France; EA 4391, Nerve Excitability and Therapeutic Team (ENT), Faculty of Medicine, Paris Est Créteil University, Créteil, France.
Department of Clinical Neurophysiology, University Medical Center, Georg-August University, Göttingen, Germany.
Clin Neurophysiol. 2017 Jan;128(1):56-92. doi: 10.1016/j.clinph.2016.10.087. Epub 2016 Oct 29.
A group of European experts was commissioned by the European Chapter of the International Federation of Clinical Neurophysiology to gather knowledge about the state of the art of the therapeutic use of transcranial direct current stimulation (tDCS) from studies published up until September 2016, regarding pain, Parkinson's disease, other movement disorders, motor stroke, poststroke aphasia, multiple sclerosis, epilepsy, consciousness disorders, Alzheimer's disease, tinnitus, depression, schizophrenia, and craving/addiction. The evidence-based analysis included only studies based on repeated tDCS sessions with sham tDCS control procedure; 25 patients or more having received active treatment was required for Class I, while a lower number of 10-24 patients was accepted for Class II studies. Current evidence does not allow making any recommendation of Level A (definite efficacy) for any indication. Level B recommendation (probable efficacy) is proposed for: (i) anodal tDCS of the left primary motor cortex (M1) (with right orbitofrontal cathode) in fibromyalgia; (ii) anodal tDCS of the left dorsolateral prefrontal cortex (DLPFC) (with right orbitofrontal cathode) in major depressive episode without drug resistance; (iii) anodal tDCS of the right DLPFC (with left DLPFC cathode) in addiction/craving. Level C recommendation (possible efficacy) is proposed for anodal tDCS of the left M1 (or contralateral to pain side, with right orbitofrontal cathode) in chronic lower limb neuropathic pain secondary to spinal cord lesion. Conversely, Level B recommendation (probable inefficacy) is conferred on the absence of clinical effects of: (i) anodal tDCS of the left temporal cortex (with right orbitofrontal cathode) in tinnitus; (ii) anodal tDCS of the left DLPFC (with right orbitofrontal cathode) in drug-resistant major depressive episode. It remains to be clarified whether the probable or possible therapeutic effects of tDCS are clinically meaningful and how to optimally perform tDCS in a therapeutic setting. In addition, the easy management and low cost of tDCS devices allow at home use by the patient, but this might raise ethical and legal concerns with regard to potential misuse or overuse. We must be careful to avoid inappropriate applications of this technique by ensuring rigorous training of the professionals and education of the patients.
国际临床神经生理学会联合会欧洲分会委托一组欧洲专家,从截至2016年9月发表的研究中收集有关经颅直流电刺激(tDCS)治疗应用现状的知识,涉及疼痛、帕金森病、其他运动障碍、运动性卒中、卒中后失语症、多发性硬化症、癫痫、意识障碍、阿尔茨海默病、耳鸣、抑郁症、精神分裂症以及渴求/成瘾等方面。基于证据的分析仅纳入了采用假tDCS对照程序进行重复tDCS治疗的研究;I类研究要求接受积极治疗的患者达到25例或更多,而II类研究接受的患者数量下限为10至24例。目前的证据不允许对任何适应症做出A级(明确疗效)推荐。对于以下情况建议给予B级推荐(可能有效):(i)纤维肌痛中,对左侧初级运动皮层(M1)进行阳极tDCS(右侧眶额叶为阴极);(ii)无药物抵抗的重度抑郁发作中,对左侧背外侧前额叶皮层(DLPFC)进行阳极tDCS(右侧眶额叶为阴极);(iii)成瘾/渴求中,对右侧DLPFC进行阳极tDCS(左侧DLPFC为阴极)。对于脊髓损伤继发的慢性下肢神经性疼痛,建议给予C级推荐(可能有效):对左侧M1进行阳极tDCS(或疼痛侧的对侧,右侧眶额叶为阴极)。相反,对于以下情况缺乏临床效果给予B级推荐(可能无效):(i)耳鸣中,对左侧颞叶皮层进行阳极tDCS(右侧眶额叶为阴极);(ii)药物抵抗的重度抑郁发作中,对左侧DLPFC进行阳极tDCS(右侧眶额叶为阴极)。tDCS可能的或潜在的治疗效果在临床上是否有意义,以及如何在治疗环境中最佳地实施tDCS,仍有待阐明。此外,tDCS设备易于操作且成本低廉,允许患者在家中使用,但这可能会引发关于潜在滥用或过度使用的伦理和法律问题。我们必须谨慎行事,通过确保对专业人员进行严格培训以及对患者进行教育,避免该技术的不当应用。